Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Timber Pharmaceuticals, Inc.BPMX · Entity 110330 | Director | January 23, 2019 | January 25, 2019 |
| Vivos Therapeutics, Inc.VVOS · Entity 8396 | Director | June 20, 2024 | June 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Timber Pharmaceuticals, Inc.
Report date January 23, 2019 · Filed January 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 1,884,126 |
Reported balance
After 2019-01-23 transaction · row 1
1 source rowRow 1 · 2019-01-23 · Sale · Disposed 115,874 · Balance 1,884,126 |
Vivos Therapeutics, Inc.
Report date June 20, 2024 · Filed June 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2029-06-20 | Direct | 7,067 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 4,000 · Balance 7,067 F1: On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2024 Filed Jun 28, 2024 20:53 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 4,000 | $2.38 Strike: $2.38 | $9,520.00 |
DisclosureSEC source: 0001493152-24-025689 · ownership.xml · derivative · entry 1 Krammer Anja B · CIK 0001418077 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,067 Underlying: Common Stock · 4,000 shares Expires 2029-06-20 F1 · derivative.exercise_date: On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 21:45 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.48 Strike: $0.48 | $14,400.00 |
DisclosureSEC source: 0001493152-22-036729 · ownership.xml · derivative · entry 1 Krammer Anja B · CIK 0001418077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,667 Underlying: Common Stock · 76,667 shares Expires 2027-12-23 F1 · derivative.exercise_date: 30,000 stock options granted on December 23, 2022. One-half vested immediately and one-eighth vests quarterly every three months through December 23, 2023. Read SEC document |
| August 05, 2021 Filed Aug 10, 2021 21:46 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $2.72 Strike: $2.72 | $81,600.00 |
DisclosureSEC source: 0001493152-21-019253 · ownership.xml · derivative · entry 1 Krammer Anja B · CIK 0001418077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,667 Underlying: Common Stock · 46,667 shares Expires 2026-08-05 F1 · derivative.exercise_date: 30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 18:55 UTC | Timber Pharmaceuticals, Inc. BPMX · Entity 110330 | SaleCommon stock | 115,874 | $0.11 | $12,746.14 |
DisclosureSEC source: 0001424422-19-000001 · primary_doc.xml · nonDerivative · entry 1 Krammer Anja B · CIK 0001418077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,884,126 Read SEC document |
| October 12, 2018 Filed Oct 12, 2018 20:02 UTC | Timber Pharmaceuticals, Inc. BPMX · Entity 110330 | SaleCommon stock | 297,500 | $0.19 | $56,525.00 |
DisclosureSEC source: 0001424422-18-000006 · primary_doc.xml · nonDerivative · entry 3 Krammer Anja B · CIK 0001418077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Read SEC document |
| October 11, 2018 Filed Oct 12, 2018 20:02 UTC | Timber Pharmaceuticals, Inc. BPMX · Entity 110330 | SaleCommon stock | 100,000 | $0.19 | $19,000.00 |
DisclosureSEC source: 0001424422-18-000006 · primary_doc.xml · nonDerivative · entry 2 Krammer Anja B · CIK 0001418077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,297,500 Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 20:02 UTC | Timber Pharmaceuticals, Inc. BPMX · Entity 110330 | SaleCommon stock | 102,500 | $0.19 | $19,475.00 |
DisclosureSEC source: 0001424422-18-000006 · primary_doc.xml · nonDerivative · entry 1 Krammer Anja B · CIK 0001418077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,397,500 Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 19:51 UTC | Timber Pharmaceuticals, Inc. BPMX · Entity 110330 | GrantOption to purchase common stock · Derivative | 1,042,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001424422-18-000002 · primary_doc.xml · derivative · entry 1 Krammer Anja B · CIK 0001418077 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,042,000 Underlying: Common stock · 1,042,000 shares Expires 2028-09-10 F1 · derivative.exercise_date: The option vests and becomes exercisable ratably over 36 months. Read SEC document |
| January 08, 2018 Filed Jan 9, 2018 18:42 UTC | Timber Pharmaceuticals, Inc. bpmx · Entity 110330 | GrantOption to purchase common stock · Derivative | 1,960,000 | $0.00 Strike: $0.11 | $0.00 |
DisclosureSEC source: 0001424422-18-000001 · primary_doc.xml · derivative · entry 1 Krammer Anja B · CIK 0001418077 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,960,000 Underlying: Common stock · 1,960,000 shares Expires 2028-01-08 F1 · derivative.exercise_date: The option vests and becomes exercisable ratably over 36 months. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 18:04 UTC | Timber Pharmaceuticals, Inc. BPMX · Entity 110330 | GrantEmployee Stock Option (right to buy) · Derivative | 940,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001140361-17-047244 · doc1.xml · derivative · entry 1 Krammer Anja B · CIK 0001418077 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 940,000 Underlying: Common Stock · 940,000 shares Expires 2027-12-20 F1 · derivative.exercise_date: The option vests and becomes exercisable ratably over 36 months Read SEC document |
| April 18, 2017 Filed Apr 19, 2017 18:00 UTC | Timber Pharmaceuticals, Inc. bpmx · Entity 110330 | GrantOption of purchase common stock · Derivative | 1,060,000 | $0.74 Strike: $0.74 | $784,400.00 |
DisclosureSEC source: 0001424422-17-000007 · primary_doc.xml · derivative · entry 1 Krammer Anja B · CIK 0001418077 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,060,000 Underlying: Common stock · 1,060,000 shares Expires 2027-04-18 F1 · security: This option vests as to 25% of the shares subject to the option on the first anniversary date of the grant with an additional 1/36th of the remaining shares vesting on the last day of each full calendar month thereafter. Read SEC document |
| December 08, 2016 Filed Dec 12, 2016 17:45 UTC | Timber Pharmaceuticals, Inc. bpmx · Entity 110330 | GrantOption to purchase common stock · Derivative | 400,000 | $0.42 Strike: $0.42 | $168,000.00 |
DisclosureSEC source: 0001424422-16-000040 · primary_doc.xml · derivative · entry 1 Krammer Anja B · CIK 0001418077 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common stock · 400,000 shares Expires 2026-12-08 F1 · security: This option vests as to 25% of the shares subject to the option on the first anniversary date of the grant with an additional 1/36th of the remaining shares vesting monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.